ClinicalTrials.gg
CompletedNCT00252785Updated Jan 24, 2011

Efficacy & Safety of Symbicort® TURBUHALER® 160/4.5 µg Twice Daily & Pulmicort® TURBUHALER® 200 µg Twice Daily + Theolong® Tablet 200 mg Twice Daily in Japanese Asthmatic Patients

A Phase 3 interventional study of Budesonide/Formoterol and Budesonide in Asthma, sponsored by AstraZeneca. Completed at 43 sites in Japan. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2011-01-24.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
340
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Enrollment
34th of 108
340 · median 124
Started
2005
with 5 others
Phase 3
51 of 110
3 open now
Registered
11th of 110
by date
Lead sponsor
41 of 110
AstraZeneca

Among the 110 studies testing budesonide in Asthma, this one is the 34th largest by enrollment of the 108 interventional ones that give a count, is one of 6 that started in 2005, is one of 51 in phase 3, and was the 11th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

The primary objective of this study is to confirm the efficacy (superiority) of Symbicort® Turbuhaler® 160/4.5 µg twice daily for 8 weeks in comparison to Pulmicort® Turbuhaler® 200 µg twice daily + Theolong® tablet 200 mg twice daily.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of asthma with a documented history of at least 6 months duration prior to Visit 1
  • Prescribed daily use of an IGCS for >=12 weeks prior to Visit 1. The dose of IGCS must be 400 to 800 µg/day of Pulmicort® Turbuhaler® or corresponding dose of IGCS. The prescribed dose of IGCS should be constant for at least 4 weeks prior to Visit 1
  • Prescribed daily use of sustained release theophylline for at least 8 weeks prior to Visit 1, or confirmed steady-state blood theophylline concentrations within the effective range (5-15 µg/mL) during 8 weeks prior to Visit 1. The prescribed dose of theophylline should be constant (400 mg/day) for at least 4 weeks prior to Visit 1

Exclusion criteria

Exclusion Criteria:

  • Any significant disease or disorder that may jeopardize the safety of the patient
  • Respiratory infection, judged by the investigator(s) as an infection affecting the asthma, within 4 weeks prior to Visit 1
  • Treatment with oral, parenteral or rectal GCS within 4 weeks prior to Visit 1

Additional inclusion and exclusion criteria will be evaluated by the Investigator

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
340 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Morning peak expiratory flow (mPEF)

Secondary outcomes

  1. Patient reported outcomes regarding disease status (incl. evening PEF), collected via diaries

  2. Forced expiratory volume in one second (FEV1)

  3. Safety:

  4. Adverse events (nature, incidence and severity)

  5. Haematology, clinical chemistry and urinalysis

  6. 12-lead ECGs, blood pressure, pulse rate

  7. - all variables assessed over the 8 week treatment period

07

Study locations

43 sites
  • Research Site
    Komaki, Aichi, Japan
  • Research Site
    Seto, Aichi, Japan
  • Research Site
    Asahi, Chiba, Japan
  • Research Site
    Noda, Chiba, Japan
  • Research Site
    Touon, Ehime, Japan
  • Research Site
    Mizumaki, Fukuoka, Japan
  • Research Site
    Isesaki, Gunma, Japan
  • Research Site
    Maebashi, Gunma, Japan
  • Research Site
    Ora, Gunma, Japan
  • Research Site
    Ota, Gunma, Japan
  • Research Site
    Chitose, Hokkaido, Japan
  • Research Site
    Kitahiroshima, Hokkaido, Japan
  • Research Site
    Obihiro, Hokkaido, Japan
  • Research Site
    Sapporo, Hokkaido, Japan
  • Research Site
    Tomakomai, Hokkaido, Japan
  • Research Site
    Morioka, Iwate, Japan
  • Research Site
    Takamatsu, Kagawa, Japan
  • Research Site
    Sendai, Miyagi, Japan
  • Research Site
    Beppu, Ohita, Japan
  • Research Site
    Tsukubo, Okayama, Japan
  • Research Site
    Kishiwada, Osaka, Japan
  • Research Site
    Oskasayama, Osaka, Japan
  • Research Site
    Takatsuiki, Osaka, Japan
  • Research Site
    Koshigaya, Saitama, Japan
  • Research Site
    Minamisaitama, Saitama, Japan
  • Research Site
    Arakawa, Tokyo, Japan
  • Research Site
    Chiyoda, Tokyo, Japan
  • Research Site
    Itabashi, Tokyo, Japan
  • Research Site
    Kodaira, Tokyo, Japan
  • Research Site
    Nakano-ku, Tokyo, Japan
  • Research Site
    Ota-ku, Tokyo, Japan
  • Research Site
    Shinagawa-ku, Tokyo, Japan
  • Research Site
    Sumida, Tokyo, Japan
  • Research Site
    Ube, Yamaguchi, Japan
  • Research Site
    Gifu, Japan
  • Research Site
    Hiroshima, Japan
  • Research Site
    Kagoshima, Japan
  • Research Site
    Kyoto, Japan
  • Research Site
    Oita, Japan
  • Research Site
    Okayama, Japan
  • Research Site
    Osaka, Japan
  • Research Site
    Tochigi, Japan
  • Research Site
    Toyama, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005 and a completion of Nov 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2005
First posted
Nov 15, 2005
Start
Oct 2005
CompletionActual
Nov 2006
Last update
Jan 24, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00252785
Lead sponsor
AstraZeneca
First posted
Nov 15, 2005
Start date
Oct 2005
Completion
Nov 2006
Last update
Jan 24, 2011

Study contacts

AstraZeneca Symbicort Medical Science Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Budesonide · Formoterol

Start the discussion